Avalo Therapeutics Unveils Pipeline Progress Highlighting Lead IL-1β Antibody for Hidradenitis Suppurativa

Reuters

2025/12/02

Avalo <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Unveils Pipeline Progress Highlighting Lead IL-1β Antibody for Hidradenitis Suppurativa

Avalo Therapeutics Inc. presented updates on its pipeline of novel IL-1β therapies for immune-mediated inflammatory diseases, highlighting its lead compound AVTX-009, an anti-IL-1β monoclonal antibody. AVTX-009 is positioned as a potential best-in-class therapy for hidradenitis suppurativa (HS), addressing unmet needs in patients with incomplete or lost response to current treatments. The company noted that AVTX-009 exhibits 15 times higher affinity and a longer half-life compared to lutikizumab, which may translate to higher efficacy and less frequent dosing. Enrollment for the Phase 2 LOTUS trial in HS is complete, with topline data expected in the second quarter of 2026. The HS market is projected to grow significantly, with additional indications for AVTX-009 under consideration. Avalo stated it has sufficient cash runway into 2028. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief on December 02, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2588032991"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2588032991\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2588032991?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-02 19:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588032991","market":"nz","top_or_hot":-1,"title":"Avalo Therapeutics Unveils Pipeline Progress Highlighting Lead IL-1β Antibody for Hidradenitis Suppurativa","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Avalo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils Pipeline Progress Highlighting Lead IL-1β Antibody for Hidradenitis Suppurativa\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/AVTX\">Avalo Therapeutics Inc</a>. presented updates on its pipeline of novel IL-1β therapies for immune-mediated inflammatory diseases, highlighting its lead compound AVTX-009, an anti-IL-1β monoclonal antibody. AVTX-009 is positioned as a potential best-in-class therapy for hidradenitis suppurativa (HS), addressing unmet needs in patients with incomplete or lost response to current treatments. The company noted that AVTX-009 exhibits 15 times higher affinity and a longer half-life compared to lutikizumab, which may translate to higher efficacy and less frequent dosing. Enrollment for the Phase 2 LOTUS trial in HS is complete, with topline data expected in the second quarter of 2026. The HS market is projected to grow significantly, with additional indications for AVTX-009 under consideration. Avalo stated it has sufficient cash runway into 2028. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief on December 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Avalo Therapeutics Unveils Pipeline Progress Highlighting Lead IL-1β Antibody for Hidradenitis Suppurativa</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAvalo Therapeutics Unveils Pipeline Progress Highlighting Lead IL-1β Antibody for Hidradenitis Suppurativa\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-02 19:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Avalo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils Pipeline Progress Highlighting Lead IL-1β Antibody for Hidradenitis Suppurativa\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/AVTX\">Avalo Therapeutics Inc</a>. presented updates on its pipeline of novel IL-1β therapies for immune-mediated inflammatory diseases, highlighting its lead compound AVTX-009, an anti-IL-1β monoclonal antibody. AVTX-009 is positioned as a potential best-in-class therapy for hidradenitis suppurativa (HS), addressing unmet needs in patients with incomplete or lost response to current treatments. The company noted that AVTX-009 exhibits 15 times higher affinity and a longer half-life compared to lutikizumab, which may translate to higher efficacy and less frequent dosing. Enrollment for the Phase 2 LOTUS trial in HS is complete, with topline data expected in the second quarter of 2026. The HS market is projected to grow significantly, with additional indications for AVTX-009 under consideration. Avalo stated it has sufficient cash runway into 2028. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief on December 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AVTX","symbol_name":"Avalo Therapeutics Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL7TL2xg:1","article_id":"2588032991","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588032991","pubTimestamp":1764673713,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Avalo Therapeutics Inc. presented updates on its pipeline of novel IL-1β therapies for immune-mediated inflammatory diseases, highlighting its lead compound AVTX-009, an anti-IL-1β monoclonal antibody. AVTX-009 is positioned as a potential best-in-class therapy for hidradenitis suppurativa , addressing unmet needs in patients with incomplete or lost response to current treatments. The company noted that AVTX-009 exhibits 15 times higher affinity and a longer half-life compared to lutikizumab, which may translate to higher efficacy and less frequent dosing. Enrollment for the Phase 2 LOTUS trial in HS is complete, with topline data expected in the second quarter of 2026. The HS market is projected to grow significantly, with additional indications for AVTX-009 under consideration. Avalo stated it has sufficient cash runway into 2028. You can access the full presentation through the link below.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AVTX":"Avalo Therapeutics Inc","BK4139":"生物科技"},"translate_title":"Avalo Therapeutics公布管道进展，重点介绍治疗化脓性汗腺炎的领先IL-1 β抗体","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVTX":0.9},"content_text":"Avalo Therapeutics Unveils Pipeline Progress Highlighting Lead IL-1β Antibody for Hidradenitis Suppurativa\n    \n\nAvalo Therapeutics Inc. presented updates on its pipeline of novel IL-1β therapies for immune-mediated inflammatory diseases, highlighting its lead compound AVTX-009, an anti-IL-1β monoclonal antibody. AVTX-009 is positioned as a potential best-in-class therapy for hidradenitis suppurativa (HS), addressing unmet needs in patients with incomplete or lost response to current treatments. The company noted that AVTX-009 exhibits 15 times higher affinity and a longer half-life compared to lutikizumab, which may translate to higher efficacy and less frequent dosing. Enrollment for the Phase 2 LOTUS trial in HS is complete, with topline data expected in the second quarter of 2026. The HS market is projected to grow significantly, with additional indications for AVTX-009 under consideration. Avalo stated it has sufficient cash runway into 2028. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief on December 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}